Biotechnology
Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities
SAN DIEGO, July 13, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion topics were about early-stage innovation assets, late-stag...
2026-07-14 00:00
3947
HKEY-AI-NAM-Bridge™ 1.0: HKeyBio Connects AI, NAMs and In Vivo Evidence
HKEY-AI-NAM-Bridge™ 1.0 connects AI predictions, new approach methodologies and in vivo evidence for more targeted preclinical study design BOSTON and SUZHOU, China, July 13, 2026 /PRNewswire/ -- HKeyBio has establishedHKEY-AI-NAM-Bridge™ 1.0, its AI and New Approach Methodologies (NAMs) In Vivo...
2026-07-13 21:16
3374
Delonix Bioworks Announces First Participant Dosed in Phase 1 Clinical Trial of Next-Generation MenB OMV Vaccine DX-104 in China
SHANGHAI, July 13, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced that the first participant has been dosed in its Phase 1 clinical trial of DX-104 in China. DX-104 is an innovative Group B menin...
2026-07-13 20:00
3005
Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline
NANJING, China, July 13, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that six of its latest research studies have been accepted for presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Congres...
2026-07-13 16:56
3272
Boostimmune Secures Japanese Patent for Sequence-Independent TCTP Antibody Technology Targeting MDSC Accumulation
* Japanese patent granted for technology that inhibits TCTP released from dead tumor cells using antibodies to suppress the accumulation of MDSCs in the tumor microenvironment * Granted claims are not expressly limited to specific antibody CDRs or amino acid sequences, but are defined by func...
2026-07-13 16:53
2547
Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-07-13 12:00
2936
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI),and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical ...
2026-07-13 08:30
3521
Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
NANJING, China, July 10, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Opamtistomig (LBL-024, a PD-L1/4-1BB bispecific antibody) as monotherapy for the treatment of adva...
2026-07-10 16:53
4483
POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare
GUANGZHOU, China, July 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its continued efforts in building an AI-powered chronic disea...
2026-07-09 20:00
4532
InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation
NANJING, China, July 9, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective...
2026-07-09 17:28
4017
WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Hebei has successfully passed the Pre-License Inspection (PL...
2026-07-09 15:31
4011
HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed. TAIPEI and SHANGHAI and SAN FRANCISCO, July 8, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827) is taking another step to broaden th...
2026-07-09 09:13
3227
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months ended June 30, 2026 ("First Half of 2026"). The s...
2026-07-09 08:30
3653
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo
HANGZHOU, China, SHANGHAI and BOSTON, July 9, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that the first patient was successfully dosed on June 30 in...
2026-07-09 08:00
4282
On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations
SAN DIEGO , July 8, 2026 /PRNewswire/ -- On the eve of the highly anticipated BIO International Convention 2026, theBIOSeedin Summer Innovation Partnering Summit successfully took place in San Diego. Hosted by bioSeedin and proudly supported by strategic partners Thermo Fisher Scientific and ACRO...
2026-07-09 00:00
2829
Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026
MONTPELLIER, France, July 8, 2026 /PRNewswire/ -- Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's leading conferences dedicated to therapeutic antibodies and biotherapeutics. At the event, the company...
2026-07-08 22:17
2991
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
* Maintained the highest MSCI AAA ESG Rating for the fourth consecutive year under the new ESG Model 5.0 (2026) * Included in the MSCI ESG Selection Indexes for the fourth consecutive year * Leader in Green CRDMO solutions for a healthier future SHANGHAI, July 8, 2026 /PRNewswire/ -- WuXi Bi...
2026-07-08 15:15
5294
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative d...
2026-07-08 10:43
3240
dsm-firmenich awards 2026 Nutrition Research Grant to five projects investigating the role of nutrients and bio-actives in supporting healthy longevity in Asia Pacific
Record number of grant applications reflect growing interest in the emerging issue of healthy aging in Asia Pacific, where one in four people will be over 60 by 2050[1]. SINGAPORE, July 8, 2026 /PRNewswire/ -- dsm-firmenich, innovators in nutrition, health, and beauty, today awarded the second r...
2026-07-08 09:00
3066
OTR Therapeutics Enters Strategic Collaboration with LG Chem to Accelerate Development of Novel Oncology Therapies
SHANGHAI, July 7, 2026 /PRNewswire/ -- OTR Therapeutics, a clinical-stage biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, today announced that it has entered into a strategic collaboration agreement with LG Chem, a leading global company ...
2026-07-08 07:00
2563
Week's Top Stories
Most Reposted
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30Agoda Launches AI-Powered Room Grid Bot to Help Travelers Decide Which Room to Book
[Picked up by 313 media titles]
2026-08-13 12:00
GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 296 media titles]
2026-08-12 16:02
Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 294 media titles]
2026-08-10 19:12
Appier Delivers Record-High Revenue, Profitability and Core Free Cash Flow
[Picked up by 294 media titles]
2026-08-13 23:42Most Read
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
16624
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
16398